期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Cytoreductive surgery and hyperthermic intraperitonealchemotherapy in gastric cancer 被引量:34
1
作者 ramakrishnan ayloor seshadri Olivier Glehen 《World Journal of Gastroenterology》 SCIE CAS 2016年第3期1114-1130,共17页
Gastric cancer associated peritoneal carcinomatosis(GCPC) has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase... Gastric cancer associated peritoneal carcinomatosis(GCPC) has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in GCPC. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery( CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) have been investigated for GCPC. HIPEC has been used for three indications in GC- as an adjuvant therapy after a curative surgery, HIPEC has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, HIPEC along with CRS is the only therapeutic modality that has resulted in longterm survival in select groups of patients; as a palliative treatment in advanced PC with intractable ascites, HIPEC has been shown to control ascites and reduce the need for frequent paracentesis. While the results of randomised trials of adjuvant HIPEC from western centres are awaited, the role of HIPEC in the treatment of GCPC is still evolving and needs larger studies before it is accepted as a standard of care. 展开更多
关键词 GASTRIC CANCER PERITONEAL CARCINOMATOSIS Cytoreductive SURGERY Hyperthermic intraperitonealchemotherapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部